| Q46705958 | A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice |
| Q38720544 | Aldosterone Production and Signaling Dysregulation in Obesity. |
| Q35765159 | Aldosterone and aldosterone antagonism in systemic hypertension |
| Q40362633 | Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. |
| Q36494721 | Aldosterone and cardiovascular disease: the heart of the matter |
| Q38263511 | Aldosterone and the heart: still an unresolved issue? |
| Q46864710 | Aldosterone antagonists in the treatment of heart failure |
| Q44075487 | Aldosterone augments endothelin-1-induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway |
| Q80675818 | Aldosterone induces circadian gene expression of clock genes in H9c2 cardiomyoblasts |
| Q35963179 | Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner |
| Q36800757 | Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction |
| Q35214540 | Aldosterone receptor antagonists for hypertension: what do they offer? |
| Q34623717 | Aldosterone receptor blockade in the management of heart failure |
| Q43788610 | Aldosterone synthase (CYP11B2) -344 C/T polymorphism is associated with left ventricular structure in human arterial hypertension |
| Q33695073 | Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function |
| Q35776759 | Alteration in accumulated aldosterone synthesis as a result of N-terminal cleavage of aldosterone synthase |
| Q44006849 | An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. |
| Q90724564 | Bioactive Candy: Effects of Licorice on the Cardiovascular System |
| Q41698053 | Biventricular Cardiac Hypertrophy in a Patient with Primary Aldosteronism and Atrial Septal Defect |
| Q43894408 | Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. |
| Q57182484 | Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised-controlled, VASERA TRIAL |
| Q35071304 | Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor |
| Q34468113 | Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study |
| Q37779717 | Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. |
| Q22007986 | Cloning and expression of a novel pH-sensitive two pore domain K+ channel from human kidney |
| Q36793743 | Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias |
| Q35173851 | Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart |
| Q84373558 | Cushing's syndrome in pregnancy |
| Q34083820 | Daily liquorice consumption for two weeks increases augmentation index and central systolic and diastolic blood pressure |
| Q41701255 | Diastolic heart failure and the extracellular matrix |
| Q35358929 | Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist |
| Q51284003 | Distribution and phenotypic expression of mineralocorticoid receptor and CYP11B2 T-344C polymorphisms in a Taiwanese hypertensive population. |
| Q43573505 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure |
| Q41977722 | Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction |
| Q85948300 | Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury |
| Q33856656 | Endothelial mineralocorticoid receptor contributes to systolic dysfunction induced by pressure overload without modulating cardiac hypertrophy or inflammation. |
| Q51300979 | Expression and biochemical characteristics of two different aldosterone receptors in both healthy and dilated cardiomyopathy dog heart tissue. |
| Q44593470 | Expression of procollagen C‐proteinase enhancer in cultured rat heart fibroblasts: Evidence for co‐regulation with type I collagen |
| Q35660795 | Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system |
| Q38817871 | Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD? |
| Q35048957 | Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? |
| Q37379344 | Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. |
| Q43197957 | Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation. |
| Q44054779 | Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure |
| Q41089677 | MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. |
| Q47265283 | Maternal obesity in the ewe increases cardiac ventricular expression of glucocorticoid receptors, proinflammatory cytokines and fibrosis in adult male offspring. |
| Q54521498 | Measured haplotype analysis of the aldosterone synthase gene and heart size. |
| Q36689814 | Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade |
| Q58722306 | Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease |
| Q34121798 | Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". |
| Q38667235 | Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats |
| Q34762461 | Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes |
| Q35087079 | Mineralocorticoid receptor expression in human venous smooth muscle cells: a potential role for aldosterone signaling in vein graft arterialization |
| Q28506467 | Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism |
| Q34132351 | Molecular signature of mineralocorticoid receptor signaling in cardiomyocytes: from cultured cells to mouse heart |
| Q37437162 | Novel pharmacotherapies to abrogate postinfarction ventricular remodeling |
| Q89748011 | Obesity and cardiovascular disease in women |
| Q37312758 | Pathological ventricular remodeling: therapies: part 2 of 2. |
| Q34336943 | Pathophysiological effects of aldosterone in cardiovascular tissues |
| Q38221451 | Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders |
| Q38316389 | Pericryptal myofibroblast growth in rat descending colon induced by low-sodium diets is mediated by aldosterone and not by angiotensin II. |
| Q52688314 | Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. |
| Q35209084 | RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease |
| Q35722993 | Rapid and MR-Independent IK1 Activation by Aldosterone during Ischemia-Reperfusion |
| Q90955920 | Rapid effects of aldosterone on platelets, coagulation, and fibrinolysis lead to experimental thrombosis augmentation |
| Q34585130 | Rationale for the use of aldosterone antagonists in congestive heart failure |
| Q39016088 | Regulation of aldosterone secretion by mineralocorticoid receptor-mediated signaling |
| Q43787206 | Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarctio |
| Q34068717 | Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes |
| Q35106487 | Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics |
| Q37433984 | Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children |
| Q37397057 | Safety and Antihypertensive Effect of Selara® (Eplerenone): Results from a Postmarketing Surveillance in Japan |
| Q37691076 | Sex-Specificity of Mineralocorticoid Target Gene Expression during Renal Development, and Long-Term Consequences |
| Q33585711 | Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction |
| Q44558742 | Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). |
| Q74315512 | Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure |
| Q33690346 | The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects |
| Q37230796 | Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease |
| Q38527834 | Treatment of Primary Aldosteronism and Organ Protection |
| Q41477573 | Voluntary liquorice ingestion increases blood pressure via increased volume load, elevated peripheral arterial resistance, and decreased aortic compliance |
| Q36639935 | Why are mineralocorticoid receptor antagonists cardioprotective? |
| Q73878711 | [Results of the RALES trial: good news for patients with heart failure and ... for health administrations] |
| Q80347519 | [What progress can be expected in the management of hypertension? Forecast from 1974 to 2034] |